Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The longer the better: follow-up in seemingly 'benign' immunoglobulin A nephropathy.

Kunter U, Floege J.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1777-1779. doi: 10.1093/ndt/gfx236. No abstract available.

PMID:
28992065
2.

Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis.

Wang J, Gibbert L, Djudjaj S, Alidousty C, Rauen T, Kunter U, Rembiak A, Enders D, Jankowski V, Braun GS, Floege J, Ostendorf T, Raffetseder U.

Kidney Int. 2016 Dec;90(6):1226-1237. doi: 10.1016/j.kint.2016.07.008. Epub 2016 Aug 31.

PMID:
27591085
3.

Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases.

Papasotiriou M, Genovese F, Klinkhammer BM, Kunter U, Nielsen SH, Karsdal MA, Floege J, Boor P.

Nephrol Dial Transplant. 2015 Jul;30(7):1112-21. doi: 10.1093/ndt/gfv063. Epub 2015 Mar 16.

PMID:
25784725
4.

From Patient to Dish and Back Again: Are We There Yet?

Kunter U, Moeller MJ.

J Am Soc Nephrol. 2015 Aug;26(8):1757-9. doi: 10.1681/ASN.2014111158. Epub 2015 Jan 7. No abstract available.

5.

The evolution of blood pressure and the rise of mankind.

Schulte K, Kunter U, Moeller MJ.

Nephrol Dial Transplant. 2015 May;30(5):713-23. doi: 10.1093/ndt/gfu275. Epub 2014 Aug 18. Review.

PMID:
25140012
6.

Mesenchymal stem cells from rats with chronic kidney disease exhibit premature senescence and loss of regenerative potential.

Klinkhammer BM, Kramann R, Mallau M, Makowska A, van Roeyen CR, Rong S, Buecher EB, Boor P, Kovacova K, Zok S, Denecke B, Stuettgen E, Otten S, Floege J, Kunter U.

PLoS One. 2014 Mar 25;9(3):e92115. doi: 10.1371/journal.pone.0092115. eCollection 2014.

7.

Albumin is recycled from the primary urine by tubular transcytosis.

Tenten V, Menzel S, Kunter U, Sicking EM, van Roeyen CR, Sanden SK, Kaldenbach M, Boor P, Fuss A, Uhlig S, Lanzmich R, Willemsen B, Dijkman H, Grepl M, Wild K, Kriz W, Smeets B, Floege J, Moeller MJ.

J Am Soc Nephrol. 2013 Dec;24(12):1966-80. doi: 10.1681/ASN.2013010018. Epub 2013 Aug 22.

8.

Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease.

Kramann R, Kunter U, Brandenburg VM, Leisten I, Ehling J, Klinkhammer BM, Knüchel R, Floege J, Schneider RK.

J Bone Miner Res. 2013 Dec;28(12):2523-34. doi: 10.1002/jbmr.1994.

9.

Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.

Villa L, Boor P, Konieczny A, Kunter U, van Roeyen CR, Denecke B, Gan L, Neusser MA, Cohen CD; ERCB Consortium;, Eitner F, Scholl T, Ostendorf T, Floege J.

J Pathol. 2013 Apr;229(5):672-84. doi: 10.1002/path.4151. Epub 2013 Mar 5.

PMID:
23192593
10.

A knotless technique for kidney transplantation in the mouse.

Rong S, Lewis AG, Kunter U, Haller H, Gueler F.

J Transplant. 2012;2012:127215. doi: 10.1155/2012/127215. Epub 2012 Jul 17.

11.

A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects.

van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, Kaitovic A, Fleckenstein S, Perbal B, Trautwein C, Weiskirchen R, Ostendorf T, Floege J.

Am J Pathol. 2012 May;180(5):1979-90. doi: 10.1016/j.ajpath.2012.01.031.

PMID:
22538190
12.

Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspects.

Scheller C, Vogel AS, Simmermacher S, Rachinger JC, Prell J, Strauss C, Reinsch M, Kunter U, Wienke A, Neumann J, Scheller K.

J Neurol Surg A Cent Eur Neurosurg. 2012 May;73(3):153-9. doi: 10.1055/s-0032-1313724. Epub 2012 May 3.

PMID:
22241592
13.

Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks.

Kunter U, Rong S, Moeller MJ, Floege J.

Kidney Int Suppl (2011). 2011 Sep;1(3):68-73. Review.

14.

Exposure to uremic serum induces a procalcific phenotype in human mesenchymal stem cells.

Kramann R, Couson SK, Neuss S, Kunter U, Bovi M, Bornemann J, Knüchel R, Jahnen-Dechent W, Floege J, Schneider RK.

Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):e45-54. doi: 10.1161/ATVBAHA.111.228601. Epub 2011 Jun 16.

PMID:
21680902
15.

Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis.

Villa L, Boor P, Konieczny A, Kunter U, van Roeyen CR, Denecke B, Gan L, Kupper MB, Hoffmann K, Eitner F, Ostendorf T, Floege J.

Nephrol Dial Transplant. 2011 Oct;26(10):3131-43. doi: 10.1093/ndt/gfr096. Epub 2011 Mar 17.

PMID:
21414972
16.

PDGF-C mediates glomerular capillary repair.

Boor P, van Roeyen CR, Kunter U, Villa L, Bücher E, Hohenstein B, Hugo CP, Eriksson U, Satchell SC, Mathieson PW, Eitner F, Floege J, Ostendorf T.

Am J Pathol. 2010 Jul;177(1):58-69. doi: 10.2353/ajpath.2010.091008. Epub 2010 May 20.

17.

Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch.

Koytchev R, Richter W, Erkent U, Kirkov V, Dimitrova V, Nern A, Kunter U.

Arzneimittelforschung. 2009;59(11):557-63. doi: 10.1055/s-0031-1296444.

PMID:
20066964
18.

Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.

Dahlke MH, Hoogduijn M, Eggenhofer E, Popp FC, Renner P, Slowik P, Rosenauer A, Piso P, Geissler EK, Lange C, Chabannes D, Mazzanti B, Bigenzahn S, Bertolino P, Kunter U, Introna M, Rambaldi A, Capelli C, Perico N, Casiraghi F, Noris M, Gotti E, Seifert M, Saccardi R, Verspaget HW, van Hoek B, Bartholomew A, Wekerle T, Volk HD, Remuzzi G, Deans R, Lazarus H, Schlitt HJ, Baan CC; MISOT Study Group.

Transplantation. 2009 Sep 15;88(5):614-9. doi: 10.1097/TP.0b013e3181b4425a.

PMID:
19741455
19.

Polyclonal immunoglobulin G ameliorates the course of progressive mesangioproliferative glomerulonephritis in rats.

Boor P, Kunter U.

Kidney Blood Press Res. 2009;32(3):169-74. doi: 10.1159/000223449. Epub 2009 Jun 9.

20.

St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.

Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A.

Eur J Clin Pharmacol. 2009 Mar;65(3):287-94. doi: 10.1007/s00228-008-0587-2. Epub 2008 Nov 18. Erratum in: Eur J Clin Pharmacol. 2009 May;65(5):541.

PMID:
19015839
21.

PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis.

Eitner F, Bücher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Bäckström G, Eriksson U, Ostman A, Floege J, Ostendorf T.

J Am Soc Nephrol. 2008 Feb;19(2):281-9. doi: 10.1681/ASN.2007030290. Epub 2008 Jan 9. No abstract available.

22.

CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation.

van Roeyen CR, Eitner F, Scholl T, Boor P, Kunter U, Planque N, Gröne HJ, Bleau AM, Perbal B, Ostendorf T, Floege J.

Kidney Int. 2008 Jan;73(1):86-94. Epub 2007 Oct 10.

23.

The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis.

Bokemeyer D, Panek D, Kitahara M, Trzaskos JM, Müller CE, Hockemeyer J, Kunter U, Boor P, Floege J, Kramer HJ, Ostendorf T.

Nephrol Dial Transplant. 2007 Dec;22(12):3431-41. Epub 2007 Sep 24.

PMID:
17893107
24.

Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes.

Kunter U, Rong S, Boor P, Eitner F, Müller-Newen G, Djuric Z, van Roeyen CR, Konieczny A, Ostendorf T, Villa L, Milovanceva-Popovska M, Kerjaschki D, Floege J.

J Am Soc Nephrol. 2007 Jun;18(6):1754-64. Epub 2007 Apr 25.

25.

Complement C5 mediates experimental tubulointerstitial fibrosis.

Boor P, Konieczny A, Villa L, Schult AL, Bücher E, Rong S, Kunter U, van Roeyen CR, Polakowski T, Hawlisch H, Hillebrandt S, Lammert F, Eitner F, Floege J, Ostendorf T.

J Am Soc Nephrol. 2007 May;18(5):1508-15. Epub 2007 Mar 27.

26.

PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis.

Boor P, Konieczny A, Villa L, Kunter U, van Roeyen CR, LaRochelle WJ, Smithson G, Arrol S, Ostendorf T, Floege J.

Nephrol Dial Transplant. 2007 May;22(5):1323-31. Epub 2007 Feb 17.

PMID:
17308324
27.

Bone marrow transplantation rescues Alport mice.

Floege J, Kunter U, Weber M, Gross O.

Nephrol Dial Transplant. 2006 Oct;21(10):2721-3. Epub 2006 Jul 22. No abstract available.

PMID:
16861735
28.

Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis.

Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, Floege J.

J Am Soc Nephrol. 2006 Aug;17(8):2202-12. Epub 2006 Jun 21.

29.

Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis.

Ostendorf T, Rong S, Boor P, Wiedemann S, Kunter U, Haubold U, van Roeyen CR, Eitner F, Kawachi H, Starling G, Alvarez E, Smithson G, Floege J.

J Am Soc Nephrol. 2006 Apr;17(4):1054-62. Epub 2006 Mar 1.

30.

Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells.

Kunter U, Daniel S, Arvelo MB, Choi J, Shukri T, Patel VI, Longo CR, Scali ST, Shrikhande G, Rocha E, Czismadia E, Mottley C, Grey ST, Floege J, Ferran C.

Kidney Int. 2005 Oct;68(4):1520-32.

31.

Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria.

Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J.

J Am Soc Nephrol. 2005 Jun;16(6):1733-41. Epub 2005 Apr 13.

32.

R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury.

Milovanceva-Popovska M, Kunter U, Ostendorf T, Petermann A, Rong S, Eitner F, Kerjaschki D, Barnett A, Floege J.

Kidney Int. 2005 Apr;67(4):1362-70.

33.

Effect of the formulation on the bioequivalence of sultamicillin: tablets and suspension.

Koytchev R, Ozalp Y, Erenmemisoglu A, Kunter U, Alpan RS.

Arzneimittelforschung. 2004 Sep;54(9A):634-9.

PMID:
15497673
34.

A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.

Ostendorf T, van Roeyen CR, Peterson JD, Kunter U, Eitner F, Hamad AJ, Chan G, Jia XC, Macaluso J, Gazit-Bornstein G, Keyt BA, Lichenstein HS, LaRochelle WJ, Floege J.

J Am Soc Nephrol. 2003 Sep;14(9):2237-47.

35.

An update on herpes virus infections in graft recipients.

Ketteler M, Kunter U, Floege J.

Nephrol Dial Transplant. 2003 Sep;18(9):1703-6. Review. No abstract available.

PMID:
12937213
36.

Extracellular actin impairs glomerular capillary repair in experimental mesangioproliferative glomerulonephritis.

Janssen U, Eitner F, Kunter U, Ostendorf T, Wolf G, Chaponnier C, Gabbiani G, Kerjaschki D, Floege J.

Nephron Exp Nephrol. 2003;93(4):e158-67.

PMID:
12759577
37.

Expression of A20 in the vessel wall of rat-kidney allografts correlates with protection from transplant arteriosclerosis.

Kunter U, Floege J, von Jürgensonn AS, Stojanovic T, Merkel S, Gröne HJ, Ferran C.

Transplantation. 2003 Jan 15;75(1):3-9.

PMID:
12544863
38.

Postischemic acute renal failure is reduced by short-term statin treatment in a rat model.

Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H.

J Am Soc Nephrol. 2002 Sep;13(9):2288-98.

39.

Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis.

Kitahara M, Eitner F, Ostendorf T, Kunter U, Janssen U, Westenfeld R, Matsui K, Kerjaschki D, Floege J.

J Am Soc Nephrol. 2002 May;13(5):1261-70.

40.

The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system.

Ostendorf T, Kunter U, van Roeyen C, Dooley S, Janjic N, Ruckman J, Eitner F, Floege J.

J Am Soc Nephrol. 2002 Mar;13(3):658-67.

41.

Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis.

Ostendorf T, Kunter U, Gröne HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J.

J Am Soc Nephrol. 2001 May;12(5):909-18.

42.

Tumour microdissemination and survival in metastatic melanoma.

Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Franzke A, Sel S, Atzpodien E, Buer J.

Anticancer Res. 2000 Sep- Oct;20(5B):3619-24.

PMID:
11131671
43.

Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.

Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A, Atzpodien J, Buer J.

Melanoma Res. 2000 Aug;10(4):355-62.

PMID:
10985670
44.

Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats.

Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, Floege J.

J Am Soc Nephrol. 2000 Apr;11(4):669-83.

45.

Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis.

Bokemeyer D, Ostendorf T, Kunter U, Lindemann M, Kramer HJ, Floege J.

J Am Soc Nephrol. 2000 Feb;11(2):232-40.

46.

Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes.

Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J.

Kidney Int. 2000 Jan;57(1):167-82.

47.

VEGF(165) mediates glomerular endothelial repair.

Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger DD, Janjic N, Floege J.

J Clin Invest. 1999 Oct;104(7):913-23.

48.

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.

Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A, Atzpodien J.

J Natl Cancer Inst. 1996 May 1;88(9):590-4.

PMID:
8609659
49.

[Absolute bioavailability of chlorpromazine, promazine and promethazine].

Koytchev R, Alken RG, Kirkov V, Neshev G, Vagaday M, Kunter U.

Arzneimittelforschung. 1994 Feb;44(2):121-5. German.

PMID:
8147942
50.

[Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat].

Vagaday M, Kunter U, Labes D, Hagen V, Böhme B, Franke P.

Pharmazie. 1994 Jan;49(1):41-7. German.

PMID:
8140129

Supplemental Content

Loading ...
Support Center